Supply of NIV Drugs for Directorate of Procurement (Navy) Islamabad

The Directorate of Procurement (Navy), Islamabad, invites sealed bids for the supply of NIV Drugs as per Tender No. 2583047/R-2511/380163/A dated 24 Oct 25. This procurement is specifically for the Directorate of Procurement (Navy) located at Naval Residential Complex, Sector E-8, Islamabad. The tender covers supply of various medical stores including Anti Rabies Human Immunoglobulin and Etoposide 100 mg ampoules/vials as detailed in the tender documents. The technical scope requires firms to submit detailed technical offers including brand names, manufacturers, and compliance with specifications. The medicines must have a minimum shelf life of two years at delivery, proper packaging, and comply with national and international standards including cold chain requirements where applicable. Inspection and quality assurance will be conducted by designated authorities including PNMSD and PNS Hafeez. Delivery is scheduled from 1st July 2026 to 30 June 2027 on a supply order basis. Eligible bidders must be registered with DGDP or willing to register, possess valid NTN and GST registration, and be on the Active Taxpayers List (ATL) of FBR. Firms must provide Earnest Money in the form of a Call Deposit Receipt as per tender conditions. Technical and commercial bids must be submitted in separate sealed envelopes following the Single Stage - Two Envelope bidding procedure. The tender opening will be held on 19th May 2026 at 1100 hours in Islamabad. Bidders are advised to carefully follow the detailed instructions regarding documentation, packaging, and submission deadlines. A practical tip for bidders is to ensure that the technical offer strictly complies with the format and specifications outlined in the tender documents, as non-compliance or incomplete documentation may lead to disqualification. Early submission and confirmation of receipt with the Directorate of Procurement (Navy) is recommended to avoid rejection due to late delivery. This tender represents a significant opportunity for pharmaceutical suppliers to engage with a key government procurement agency under clear and structured terms. The earnest money, technical scrutiny, and evaluation criteria are designed to ensure transparency and quality in the procurement process.